by John Conrad | Mar 2, 2020 | COVID
Drugs previously in development for SARS could be effective for COVID-19 A potential drug target has been identified in a newly mapped protein of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19). The structure was solved by a team including the...
by John Conrad | Jan 31, 2020 | Member News
What happens when a highly interdisciplinary and integrated team of scientists, business leaders and students work together across fields of fundamental science, discovery, development, and finance? In the case of Monopar Therapeutics, a Chemistry of Life Processes...
by John Conrad | Dec 4, 2019 | Member News
Veteran entrepreneurs and cofounders of Actuate Therapeutics, Inc., Daniel Schmitt and Andrew Mazar, PhD, are taking no chances with their lead clinical candidate 9-ING-41, a promising new treatment for advanced and drug-resistant cancers and select inflammatory...
